Heart rate variability (HRV) — the subtle variation in timing between heartbeats — is one of medicine's most sensitive indicators of autonomic nervous system health. It's tracked by elite athletes, cardiologists, and increasingly by consumer wearables. It's also the metric that a Trent University scientist used to evaluate the effect of Wi-Fi EMF exposure on the human cardiovascular system — under double-blind, placebo-controlled conditions.
The Havas Studies: Background
Dr. Magda Havas is a researcher at Trent University (Canada) specializing in the biological effects of electromagnetic pollution. In 2015, she conducted two case studies examining cardiovascular responses to Wi-Fi EMF exposure, using the Aires Defender Infinity resonator as the intervention variable.
Both studies used MaxPulse — an FDA Class II cleared cardiac monitor — as the primary measurement tool. This is important: MaxPulse is a regulated medical device, not a consumer gadget, used in clinical cardiovascular assessment. The data it produces is objective, quantifiable, and replicable.
Study Design: Double-Blind and Placebo-Controlled
Case Study 1 enrolled a 52-year-old female subject who self-identified as electromagnetically hypersensitive (EHS). The design was rigorous:
- Blinding: Neither the subject nor the experimenter knew whether the active device or a sham device was in use during each measurement session
- Placebo control: Sessions alternated between active device and sham (physically identical but non-functional) device — controlling for expectation effects
- Standardized protocol: Each session followed an identical measurement sequence with the same Wi-Fi EMF source
The results showed significant cardiovascular differences between active and sham conditions — measured by MaxPulse parameters including heart rate, HRV frequency domain metrics, and autonomic balance indicators.
Case Study 2: Replication in a Non-EHS Subject
The second case study enrolled a 46-year-old female subject who did not report electromagnetic hypersensitivity. This is significant: it tested whether the cardiovascular effects of Wi-Fi EMF exposure and resonator modulation were limited to self-identified sensitive individuals, or present in the general population.
Case Study 2 also used GDV Bio-Well imaging as an additional measurement modality alongside MaxPulse. Results again showed measurable differences between exposure conditions.
What This Research Demonstrates
The Havas studies represent some of the most methodologically rigorous research in the Aires corpus. Key strengths:
- Independent researcher (university-affiliated, not Aires-employed)
- Blinded protocol (both subject and experimenter blinded)
- Medical-grade measurement instrument (FDA Class II device)
- Objective physiological endpoints (cardiovascular parameters, not self-reported symptoms)
The finding: Wi-Fi EMF exposure measurably affects cardiovascular parameters in the tested subjects, and the Aires resonator significantly moderates those effects compared to the sham condition.
HRV and Electromagnetic Hypersensitivity
The WHO notes that controlled studies have not consistently confirmed a link between self-reported EHS symptoms and EMF exposure. The Havas study is notable because it measured objective cardiovascular endpoints — not self-reported symptoms — in an EHS subject under blinded conditions. The data showed a physiological difference that the subject's self-perception alone could not have produced.
Read the Full Studies
→ Havas Case Study 1: 52-Year-Old EHS Subject (Trent University, 2015)
→ Havas Case Study 2: 46-Year-Old Female Subject (Trent University, 2015)